ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 166 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2018. The put-call ratio across all filers is 9.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $435,000 | -32.2% | 5,169 | -27.4% | 0.00% | -33.3% |
| Q3 2021 | $642,000 | -5.4% | 7,118 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $679,000 | -40.4% | 7,118 | -28.8% | 0.00% | -40.0% |
| Q1 2021 | $1,139,000 | -56.2% | 10,004 | -46.7% | 0.01% | -54.5% |
| Q4 2020 | $2,600,000 | +69.4% | 18,781 | +0.5% | 0.01% | +57.1% |
| Q3 2020 | $1,535,000 | +28.1% | 18,680 | +21.9% | 0.01% | +16.7% |
| Q2 2020 | $1,198,000 | +106.6% | 15,320 | +17.3% | 0.01% | +50.0% |
| Q1 2020 | $580,000 | +134.8% | 13,060 | +126.0% | 0.00% | +300.0% |
| Q3 2019 | $247,000 | -32.7% | 5,780 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $367,000 | -67.6% | 5,780 | -64.6% | 0.00% | -66.7% |
| Q1 2019 | $1,132,000 | +50.3% | 16,320 | -5.8% | 0.01% | +20.0% |
| Q4 2018 | $753,000 | -37.6% | 17,320 | +9.6% | 0.01% | -16.7% |
| Q3 2018 | $1,207,000 | +9.3% | 15,805 | +10.0% | 0.01% | 0.0% |
| Q2 2018 | $1,104,000 | +46.8% | 14,365 | -2.6% | 0.01% | +50.0% |
| Q1 2018 | $752,000 | – | 14,745 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| EcoR1 Capital, LLC | 519,119 | $40,605,000 | 3.00% |
| First Light Asset Management, LLC | 236,958 | $18,535,000 | 2.16% |
| SECTOR GAMMA AS | 108,734 | $8,505,000 | 1.76% |
| Rock Springs Capital Management LP | 646,841 | $50,596,000 | 1.39% |
| Atika Capital Management LLC | 79,000 | $6,180,000 | 0.80% |
| Capital Impact Advisors, LLC | 30,582 | $2,392,000 | 0.80% |
| FEDERATED HERMES, INC. | 4,080,359 | $319,166,000 | 0.79% |
| Rhenman & Partners Asset Management AB | 61,500 | $4,811,000 | 0.52% |
| Ikarian Capital, LLC | 73,500 | $5,749,000 | 0.46% |
| Capital International, Inc./CA/ | 477,858 | $37,378,000 | 0.46% |